Genmab A/S (GMAB) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the GENmaps financial results conference call for the first quarter of 2025. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as beliefs, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. GENmaps is not under any obligation to update statements regarding the future, not to confirm such statements in relation to actual results, unless this is required by law. Please also note that GENMAP may hold your personal data as indicated by you as a part of our investor relations outreach activities in order to update you on GENMAP going forward. Please refer to our website for more information on GENMAP and our privacy policy. I would now like to hand the conference over to our first speaker today, Jan van de Winkel. Please go ahead. Hello, and welcome to GenMob's conference call to discuss our financial results for the period ending March 31st, 2025. With me today to present these results is our Chief Financial Officer, Anthony Pagano, our Chief Commercial Officer, Brad Bailey, and our Chief Medical Officer, Tai Yamadi. For the Q&A, we will be joined by our Chief Development Officer, Judith Klimowski. As already said, we will be making forward-looking statements, so please keep that in mind as we go through this call. During today's presentation, we will reference products being developed under some of our strategic collaborations, and this slide acknowledges those relationships. In 2025, we continue to advance towards becoming a fully integrated biotech, independently developing and commercializing wholly owned antibody differentiated therapies. Ou...